Dagens Nyheter har en artikelserie om BDD där flera av våra medarbetare är med.
Läs här (IntrenetKBT med Jesper Enander) eller här (BDD och män med Christian Rück).
Author: Christian Rück
Doctor Jesper Enander defended his thesis!
Jesper Enander today received his PhD after successfully defending his thesis today. Congratulations Jesper!
Jesper (the tallest) surrounded by his supervisors. To the left the opponent Prof Ulrike Buhlmann being distracted by Prof Jerker Hetta from the examination board.
The examination board: Klaas Wijma, Linköping University, Jerker Hetta and Kalle Lundgren, KI.
Showtime.
It’s done.
Manuel Mattheisen joins our group
Our collaborator Manuel Mattheisen, Associate Professor at Århus University, is now officially affiliated to Karolinska Institutet and our group. He studied medicine at the University in Bonn and went on to be a research follow at Harvard Medical School before moving to Denmark. We are fortunate to enjoy his deep expertise in genetical methods. Check out his quite spectacular publication list here.
Jesper nailed his thesis!
Jesper Enander just nailed his thesis to a plank at the Karolinska library. This means that the thesis is now open to the public and will be publicly defended May 5th.
Best publication of the year awarded to….
Our treatment study of Body Dysmorphic Disorder published in the BMJ was yesterday awarded the best publication of the year by the Department of Clinical Neuroscience at Karolinska Institutet!
Jesper Enander graciously holding the award.
Jesper Enander to defend thesis on May 5th
Jesper is about to defend his thesis titled: “Etiology, prevalence, and development of a novel treatement for body dysmorphic disorder” May 5 at 09.00 in Lecture hall H1, Alfred Nobels Allé 23, Campus Flemingsberg. Do not miss!
His Opponent will be Professor Ulrike Buhlman, University of Münster.
Examination Board:
Associate Professor Kalle Lundgren, Karolinska Institutet, Department of Molecular Medicine and Surgery
Professor Klaas Wijma, Linköping University, Department of Clinical and Experimental Medicine
Professor Jerker Hetta, Karolinska Institutet, Department of Clinical Neuroscience
Principal Supervisor:
Associate Professor Christian Rück, Karolinska Institutet, Department of Clinical Neuroscience
Co-supervisors:
Professor David Mataix-Cols, Karolinska Institutet, Department of Clinical Neuroscience
Professor Paul Lichtenstein, Karolinska Institutet, Department of Medical Epidemiology and Biostatistics
Associate Professor Brjánn Ljótsson, Karolinska Institutet, Department of Clinical Neuroscience
Fabian Lenhard to defend thesis
Don’t miss our dearest Fabian Lenhard’s thesis
Internet-delivered cognitive behavior therapy for adolescents with obsessive-compulsive disorder
to be publicly defended Friday March 23. Details on where here: http://ki.se/cns/kalender/disputation-fabian-lenhard
Your can download his thesis here: https://openarchive.ki.se/xmlui/handle/10616/45535
First Swedish dissertation on Body Dysmorphic Disorder
Sabina Brohede of Linköping University has just defended the first ever dissertation on Body Dysmorphic Disorder ever. Congratulations Sabina! Below her work explained in 4 wooden figures. 
Interested in treatment (in English) for Body Dysmorphic Disorder?
We have just opened up our treatment study of internet-based cognitive behavioural therapy for international participants. The treatment is in English. Read more about it at: https://bddstudy.com
New meta-analysis in JAMA Psychiatry: Does d-cycoserine add to CBT?
D-cycloserine (DCS) is a partial NMDA agonist that facilitates fear extinction in animals and reduces return of fear when given before extinction training. Despite several initial trials showing promising results in humans with anxiety disorders larger trials conducted within the past 5 years have produced mixed results. Our large trial in obsessive-compulsive disorder22 found no general effect of DCS but a significant interaction effect between DCS and antidepressant medication in a post hoc analysis; antidepressants impaired treatment response in patients randomized to DCS but not in patients randomized to placebo.
We collected Individual participant data for 21 of 22 DCS trials, representing 1047 of 1073 eligible participants. When controlling for antidepressant use, participants receiving DCS showed greater improvement from pretreatment to posttreatment (mean difference, −3.62; 95% CI, −0.81 to −6.43; P = .01; d = −0.25) but not from pretreatment to midtreatment (mean difference, −1.66; 95% CI, −1.60 to 4.92; P = .32; d = −0.14) or from pretreatment to follow-up (mean difference, −2.98, 95% CI, −0.03 to 5.99; P = .05; d = −0.19). Only 1 significant moderator emerged: year of publication. Specifically, the more recent the study, the smaller the difference between DCS and placebo for pretreatment to follow-up improvement (b = 4.02; 95% CI, 0.59-7.45; P = .02, d = 0.26).
Conclusion: D-cycloserine is associated with a small augmentation effect on exposure-based therapy. The small size of the effect makes the clinical usefulness of DCS doubtful.
Mataix-Cols D, Fernández de la Cruz L, Monzani B, Rosenfield D, Andersson E, Pérez-Vigil A, Frumento P, de Kleine RA, Difede J, Dunlop BW, Farrell LJ, Geller D, Gerardi M, Guastella AJ, Hofmann SG, Hendriks G, Kushner MG, Lee FS, Lenze EJ, Levinson CA, McConnell H, Otto MW, Plag J, Pollack MH, Ressler KJ, Rodebaugh TL, Rothbaum BO, Scheeringa MS, Siewert-Siegmund A, Smits JAJ, Storch EA, Ströhle A, Tart CD, Tolin DF, van Minnen A, Waters AM, Weems CF, Wilhelm S, Wyka K, Davis M, Rück C, for the DCS Anxiety Consortium. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress DisordersA Systematic Review and Meta-analysis. JAMA Psychiatry. Published online January 25, 2017. doi:10.1001/jamapsychiatry.2016.3955
